Tofogliflozin, a novel sodium–glucose co‐transporter 2 inhibitor, improves renal and pancreatic function in db/db mice
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background and Purpose: Although inhibition of renal sodium–glucose co‐transporter 2 (SGLT2) has a stable glucose‐lowering effect in patients with type 2 diabetes, the effect of SGLT2 inhibition on renal dysfunction in type 2 diabetes remains to be determined. To evaluate the renoprotective effect of SGLT2 inhibition more precisely, we compared the effects of tofogliflozin (a specific SGLT2 inhibitor) with those of losartan (an angiotensin II receptor antagonist) on renal function and beta‐cell function in db/db mice. Experimental Approach: The effects of 8‐week tofogliflozin or losartan treatment on renal and beta‐cell function were investigated in db/db mice by quantitative image analysis of glomerular size, mesangial matrix expansion and islet beta‐cell mass. Blood glucose, glycated Hb and insulin levels, along with urinary albumin and creatinine were measured Key Results: Tofogliflozin suppressed plasma glucose and glycated Hb and preserved pancreatic beta‐cell mass and plasma insulin levels. No improvement of glycaemic conditions or insulin level was observed with losartan treatment. Although the urinary albumin/creatinine ratio of untreated db/db mice gradually increased from baseline, tofogliflozin or losartan treatment prevented this increase (by 50–70%). Tofogliflozin, but not losartan, attenuated glomerular hypertrophy. Neither tofogliflozin nor losartan altered matrix expansion. Conclusions and Implications: Long‐term inhibition of renal SGLT2 by tofogliflozin not only preserved pancreatic beta‐cell function, but also prevented kidney dysfunction in a mouse model of type 2 diabetes. These findings suggest that long‐term use of tofogliflozin in patients with type 2 diabetes may prevent progression of diabetic nephropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369 · cited 2×
“…end-products (Cooper, 2001), is a major micro-vascular complication in type 2 diabetes patients, and intensive glycaemic control to prevent the progression of DN is recommended (The DCCT Research Group, 1993; UKPDS Group, 1998; National Kidney Foundation, 2007; American Diabetes Association, 2013).”
BackgroundAnimal research: Reporting in vivo experiments: The ARRIVE guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00872.x · Cited by 3,625
Animal Research: Reporting in vivo Experiments—The ARRIVE Guidelines
Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M., & Altman, D. G. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.220 · Cited by 2,012
(2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.12.005 · Cited by 1,788
Guidelines for reporting experiments involving animals: the ARRIVE guidelines
McGrath, J., Drummond, G., McLachlan, E., Kilkenny, C., & Wainwright, C. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00873.x · Cited by 1,592
Biology of Human Sodium Glucose Transporters
Wright, E. M., Loo, D. D. F., & Hirayama, B. A. (2011) · Physiological Reviews · doi:10.1152/physrev.00055.2009 · Cited by 1,430
Vallon, V., & Thomson, S. C. (2012) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020911-153333 · Cited by 376
Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy
Cooper, M. E. (2001) · Diabetologia · doi:10.1007/s001250100000 · Cited by 375 · cited 2×
“Renal failure caused by chronic hyperglycaemia via metabolic factors, such as increased oxidative stress, renal polyol formation and advanced glycated end-products (Cooper, 2001), is a major micro-vascular complication in type 2 diabetes patients, and intensive glycaemic control to prevent the progression of DN is rec…”
BackgroundVallon, V., Rose, M., Gerasimova, M., Satriano, J., Platt, K. A., Koepsell, H., Cunard, R., Sharma, K., Thomson, S. C., & Rieg, T. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00409.2012 · Cited by 370
Devenny, J. J., Godonis, H. E., Harvey, S. J., Rooney, S., Cullen, M. J., & Pelleymounter, M. A. (2012) · Obesity · doi:10.1038/oby.2012.59 · Cited by 212 · cited 6×
“, 2013) and in diet-induced obese rats (Devenny et al., 2012) and KKAy mice, a mouse model of type 2 diabetes without betacell loss with aging (Katsuno et al.”
BackgroundInfluential
Cited by
Vallon, V., & Thomson, S. C. (2017) · Diabetologia · doi:10.1007/s00125-016-4157-3 · Cited by 635
Lin, B., Koibuchi, N., Hasegawa, Y., Sueta, D., Toyama, K., Uekawa, K., Ma, M., Nakagawa, T., Kusaka, H., & Kim-Mitsuyama, S. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0148-1 · Cited by 423
“Our present results are in good agreement with previous reports regarding various SGLT2 inhibitors [17-19,41,44] including empagliflozin [16].”
Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences
Gallo, L. A., Wright, E. M., & Vallon, V. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114561992 · Cited by 395
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
Heerspink, H. J. L., Kosiborod, M., Inzucchi, S. E., & Cherney, D. Z. I. (2018) · Kidney International · doi:10.1016/j.kint.2017.12.027 · Cited by 393
Terami, N., Ogawa, D., Tachibana, H., Hatanaka, T., Wada, J., Nakatsuka, A., Eguchi, J., Horiguchi, C. S., Nishii, N., Yamada, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100777 · Cited by 341
Metadata
- Authors
- Nagata, T., Fukuzawa, T., Takeda, M., Fukazawa, M., Mori, T., Nihei, T., Honda, K., Suzuki, Y., & Kawabe, Y.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2013-09-17
- Volume
- 170
- Issue
- 3
- Pages
- 519-531
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1603802113
- Cited by
- 88
- References
- 10
- FWCI
- 9.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tofogliflozin, a novel sodium–glucose co‐transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. https://app.cochat.ai/papers/10.1111/bph.12269
- The paper
- Nagata, T., Fukuzawa, T., Takeda, M., Fukazawa, M., Mori, T., Nihei, T., Honda, K., Suzuki, Y., & Kawabe, Y. (2013). Tofogliflozin, a novel sodium–glucose co‐transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. British Journal of Pharmacology. https://doi.org/10.1111/bph.12269
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.